BETHESDA, Md. – An FDA advisory panel Friday said it would be too risky to permit Jazz Pharmaceuticals Inc. to market its oral liquid sodium oxybate drug under two names in two different concentrations for separate indications due to the risk of dual prescribing leading to overdose, in addition to the medicine's already known potential for misuse and abuse. (BioWorld Today) Read More
